Cerebral small vessel disease
Conditions
Interventions
Sponsors
The Seventh Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
46 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Cerebral small vessel disease group: aged 46-75 years, with or without cognitive impairment and other damage symptoms/signs, brain MRI showed white matter hyperintensity (WMH) Fazekas scale score = 1 with lacunar, enlarged perivascular spaces, cerebral microbleeds or brain atrophy, or Fazekas scale score >= 2 with or without lacunar, enlarged perivascular spaces, cerebral microbleeds or brain atrophy. 2.Essential hypertension group: aged 46-75 years, diagnosed with hypertension and treated with medication for a long time, or patients with continuous monitoring of systolic/diastolic blood pressure >= 140/90 mmHg on 3 consecutive days without cognitive impairment and symptoms/signs of brain damage, and cranial MRI does not meet the criteria for CSVD diagnosis. 3.Type 2 diabetes mellitus group: aged 46-75 years, meeting the diagnostic criteria for diabetes mellitus type 2, without cognitive impairment and symptoms/signs of brain damage, and cranial MRI does not meet the diagnostic criteria for CSVD. 4.Normal control group: aged 46-75 years,healthy people and outpatients/inpatients without basic medical history, clinical symptoms, and evidence of pathological changes in brain MRI.
Exclusion criteria
Exclusion criteria: 1.Cerebral small vessel disease group: 1) Patients with cognitive impairment that may be caused by Alzheimer's disease according to the National Institute on Aging criteria. 2) Patients with subcortical small infarcts or lacunar infarcts within 3 months after stroke. 3) Patients with CSVD caused by other independent factors (e.g., genetic, inflammatory, thrombotic, systemic, toxic, history of severe migraine). 4) Patients with stroke and accompanying neurological deficit symptoms caused by other causes of CSVD. 5) Patients with atherosclerotic stenosis >50% on brain MRA and carotid artery color Doppler ultrasonography. 6) Patients with severe comorbidities—heart (ejection fraction 50%, combined with infection, peripheral arterial disease, chronic kidney disease, myocardial infarction, stroke, diabetes, tumor and other medical history. 3.Type 2 diabetes mellitus group: Exclusion of patients with hypertension, acute coronary syndrome or stroke, atherosclerotic stenosis >50% on brain MRA and carotid artery color Doppler ultrasound, currently receiving oral anticoagulant therapy or with a history of Raynaud's phenomenon.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the level of GSH and GSSG in red blood cells;the level of NO, ROS and RNS in plasma;the rheological properties of erythrocytes;the level of vWF and S100-ß in plasma;eNOS expression and eNOS uncoupling; | — |
Countries
China
Contacts
Public ContactBi-Jun Mao
The Seventh Affiliated Hospital of Southern Medical University
Outcome results
None listed